STOCK TITAN

Revolution Medicines, Inc. Stock Price, News & Analysis

RVMD Nasdaq

Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.

Revolution Medicines, Inc. (RVMD) is a clinical-stage biotechnology company pioneering targeted therapies for cancers driven by RAS mutations. This page serves as the definitive source for verified news and developments related to the company's precision oncology programs.

Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and scientific advancements in RAS pathway inhibition. Our curated collection includes press releases on drug discovery breakthroughs, partnership announcements, and peer-reviewed research findings.

Key focus areas include updates on the company's RAS(ON) inhibitor portfolio, mTOR signaling developments, and strategic collaborations advancing cancer treatment innovation. All content is vetted for accuracy and relevance to provide reliable insights into RVMD's evolving pipeline.

Bookmark this page for structured access to essential updates about Revolution Medicines' progress in addressing unmet needs in oncology through its evolution-inspired therapeutic approaches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
conferences earnings
-
Rhea-AI Summary

Revolution Medicines, a clinical-stage oncology company focused on targeted therapies for RAS-addicted cancers, will feature CEO Mark A. Goldsmith in a fireside chat at the 22nd Annual Needham Healthcare Conference from April 17-20, 2023. The chat is scheduled for 3:00 p.m. Eastern on April 20, 2023, and will be held virtually with a webcast available. Interested parties can access the live presentation and the subsequent replay on the company’s website for at least 14 days after the event.

The company specializes in developing RAS(ON) Inhibitors aimed at various oncogenic RAS protein variants, with RMC-6236 and RMC-6291 currently in clinical development. Additional pipeline candidates target other RAS mutations and include RAS Companion Inhibitors for combination therapies. For further details, visit Revolution Medicines Events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences
Rhea-AI Summary

Revolution Medicines, Inc. (Nasdaq: RVMD) announced it will present significant preclinical data at the AACR Annual Meeting 2023, taking place from April 14-19, 2023, in Orlando, Florida. Notable presentations include the discovery of RMC-6291, a tri-complex KRAS G12C inhibitor, and RMC-9805, a first-in-class mutant-selective KRAS G12D inhibitor that synergizes with immunotherapy in preclinical models. These innovations aim to address RAS-addicted cancers, showcasing the company's commitment to developing targeted oncological therapies. The presentations are scheduled for April 16 and 17, highlighting advancements in cancer treatment that could significantly impact future clinical strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
conferences clinical trial

FAQ

What is the current stock price of Revolution Medicines (RVMD)?

The current stock price of Revolution Medicines (RVMD) is $38.02 as of July 11, 2025.

What is the market cap of Revolution Medicines (RVMD)?

The market cap of Revolution Medicines (RVMD) is approximately 7.1B.
Revolution Medicines, Inc.

Nasdaq:RVMD

RVMD Rankings

RVMD Stock Data

7.05B
181.47M
2.06%
106.38%
8.52%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
REDWOOD CITY